Date: 2012-03-06
Type of information:
phase:
Announcement: results
Company: Epigenomics (Germany-USA)
Product: ARUP Septin9 test
Action mechanism:
Disease: colorectal cancer
Therapeutic area: Cancer Oncology
Country: USA
Trial details: The study assessed the attitudes and preferences of 100 participants eligible for CRC screening of which 44% were previously unscreened, with respect to screening by FOBT, sigmoidoscopy, colonoscopy or Septin9 blood testing. In this focus group study, participants completed a survey after a 90 minute moderated discussion about the procedure, cost and accuracy of all tests.
Latest
news: Epigenomics has announced that results of a survey on colorectal cancer (CRC) screening preferences conducted by Jennifer Taber et al. (Department of Psychology University of Utah, Huntsman Cancer Institute, ARUP Laboratories) were presented at the American Society for Preventive Oncology 2012 Annual Meeting in Washington, DC on March 5, 2012. The survey indicated that given the performance of the ARUP Septin9 test (90% sensitive, 89% specific; Warren et al. 2011) and its cost of approximately $180, two thirds of previously unscreened subjects would prefer a Septin9 blood test to other screening methods. Noel Doheny, CEO of Epigenomics’ US subsidiary and member of the Epigenomics Senior Management Team noted: “The study demonstrates that the convenience of a blood based test should lead to a greater acceptance and thus a higher compliance to colorectal cancer screening. It underlines the value that blood-based Septin9 tests can potentially bring as alternative for the detection of colorectal cancer”.
Among the positive aspects of the test, participants noted its convenience (62%), cost (52%) and accuracy (55%). Among the negative factors of the test, participants mentioned the inability to detect precancerous polyps (6%) and lack of insurance coverage (6%).
